Source comparison
Thymosin Alpha-1 BPC-157 for Lyme Research: Comparison Table
Thymosin Alpha-1 Immunomodulation via TLR9 activation Th1/Th2 balance restoration, Treg upregulation Increased IL-2 production (+180% vs baseline in murine models), restored CD4+ T-cell counts Corrects the Th2 shift and Treg suppression documented in PTLDS pat
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- Immunomodulation via TLR9 activation
- Th1/Th2 balance restoration, Treg upregulation
- Increased IL-2 production (+180% vs baseline in murine models), restored CD4+ T-cell counts
- Corrects the Th2 shift and Treg suppression documented in PTLDS patients
- Most compelling for immune reconstitution in chronic Lyme. Addresses the core T-cell dysfunction antibiotics don't touch
- BPC-157
- Anti-inflammatory via NF-kB inhibition and gut barrier repair
- Tight junction stabilization, nitric oxide pathway modulation
- TNF-alpha reduction (62% in LPS challenge models), ZO-1 upregulation (89% restoration in 72 hours)
- Repairs intestinal permeability that amplifies systemic inflammation and perpetuates PTLDS symptoms
- Critical for breaking the gut-inflammation cycle. Without barrier repair, immune modulation alone shows limited durability
- Combined Approach
- Dual-pathway targeting: immune correction + inflammation suppression
- Simultaneous Th1 restoration and NF-kB inhibition with barrier repair
- No published human trials yet; preclinical data suggests additive rather than synergistic effects
- Addresses both immune dysregulation and the structural damage driving persistent inflammation
- Mechanistically sound but clinically unproven. Early-stage research with strong biological rationale but no Phase II data yet